Products

Earnings
API

Get in Touch

Contact Us
X (Twitter)
LinkedIn

Resources

Disclaimer: CapyFin provides financial data and AI analysis for informational purposes only and does not provide investment advice or recommendations. Real-time data and AI outputs may be inaccurate, incomplete, delayed, or contain errors or hallucinations. Investing involves risk, including loss of principal. The service is provided “as is” and we disclaim liability to the fullest extent permitted by law. See our Terms of Service and Privacy Policy.

Viking Therapeutics Fiscal Q3 2023 Earnings Report - CapyFin

Viking Therapeutics

🇺🇸 NASDAQ:VKTX

View Company

Overview Earnings Dividends Seasonality Metrics

Oct 25, 2023

•

Sep 30, 2023

Viking Therapeutics Q3 2023 Earnings Report

Viking Therapeutics reported financial results for Q3 2023 and provided a corporate update.

Key Takeaways

Viking Therapeutics reported a net loss of $22.5 million, or $0.23 per share, for the third quarter ended September 30, 2023. The company's cash position remained strong at $376 million. Clinical trials for VK2735 and VK2809 are progressing, with results expected in 1H24.

Phase 2 VENTURE Trial of GLP-1/GIP Agonist VK2735 in Obesity Fully Enrolled; Results Expected 1H24

Phase 2b VOYAGE Study Evaluating VK2809 for the Treatment of NASH and Fibrosis Ongoing; Histology Results Expected 1H24

Phase 1 Trial of Oral VK2735 Continues to Enroll; Results Expected 1Q24

Strong Quarter-End Cash Position of $376M

Total Revenue

EPS

-$0.23

Previous year: -$0.21